Hypoxia-inducible factor (HIF) inhibitors: A patent survey (2011-2015)

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 3, 2016, Pages 309-322

  Ban, Hyun Seung ^a   Uto, Yoshikazu ^b   Won, Misun ^a   Nakamura, Hiroyuki ^c  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b DAIICHI SANKYO CO   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

cancer; Carcinogenesis; HIF inhibitors; hypoxia; hypoxia inducible factor (HIF)

Indexed keywords

2 METHOXYESTRADIOL; 3 [2 [4 (4,4' DIFLUOROBENZHYDRYLIDENE)PIPERIDINO]ETHYL] 2,3 DIHYDRO 2 THIOXO 4(1H) QUINAZOLINONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ALVESPIMYCIN; AROMATIC COMPOUND; BENZOPYRAN DERIVATIVE; CORTICOSTEROID ANTAGONIST; DISULFIDE; ECHINOMYCIN; EMETINE; ESTER DERIVATIVE; GELDANAMYCIN; GLYCOLYTIC ENZYME; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; LIFICIGUAT; NATURAL PRODUCT; PROTEIN INHIBITOR; ROXADUSTAT; SULFONAMIDE; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

CANCER CELL; CANCER STAGING; CANCER THERAPY; DRUG MECHANISM; DRUG STRUCTURE; ENERGY YIELD; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; NON SMALL CELL LUNG CANCER; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; GENETICS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATENTS AS TOPIC;

EID: 84959322427     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2016.1146252     Document Type: Review

References (125)

1. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(Suppl 5):4-9.
2. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8(4 Suppl):S62-S67.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003 Oct;3(10):721-732.
4. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000 Jul;2(7):423-427.
5. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468.
6. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002;277 (29):26351-26355.
7. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol. 2004;30(5):465-468.
8. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14(1):34-44.
9. Semenza GL. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets. 2006;10(2):267-280.
10. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res. 2003;93(2):96-105.
11. Teng CM, Wu CC, Ko FN, et al. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol. 1997;320(2-3):161-166.
12. Galle J, Zabel U, Hubner U, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol. 1999;127(1):195-203.
13. DeNiro M, Al-Halafi A, Al-Mohanna FH, et al. Pleiotropic effects of YC- 1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygeninduced retinopathy. Mol Pharmacol. 2010;77(3):348-367.
14. Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol. 2001;61(8):947-954.
15. Kuo S-C, Lee F-Y, Teng C-M, et al., inventors; Yung Shin Pharm. Ind. Co., Ltd., Taiwan. assignee. Method for inhibiting EZH2 expression in breast cancer cells using YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole) or its succinate ester patent WO2014193930A1. 2014.
16. Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871-874.
17. Deb G, Singh AK, Gupta S. EZH2: not EZHY (easy) to deal. Mol Cancer Res. 2014;12(5):639-653.
18. Al-Mohanna F, Deniro M, inventors; King Faisal Specialist Hospital and Research Centre, Saudi Arabia; Terramark Markencreation GmbH; King Khalid Eye Specialist Hospital. assignee. Pyrazolyl compounds for use in reversing reactive gliosis patent WO2012152295A1. 2012.
19. Jordan BF, Runquist M, Raghunand N, et al. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res. 2005;11(2 Pt 1):529-536.
20. Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med. 2003;142(1):46-51.
21. Welsh SJ, Williams RR, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003;2(3):235-243.
22. Pearlman E, Leal SM Jr, inventors; Case Western Reserve University, USA. assignee. Thioredoxin protein inhibitors for treatment of fungal infections patent WO2013158892A1. 2013.
23. Georgopoulos N, inventor; University of Huddersfield, UK. assignee. Composition comprising a tumor necrosis factor receptor (TNFR) agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma patent WO2014118578A1. 2014.
24. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9 (5):361-371.
25. Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxiainducible factor-1alpha. Mol Cancer Ther. 2004;3(3):233-244.
26. Filippini A, Riccioli A, Paone A, et al., inventors; Universita degli Studi di Roma "La Sapienza", Italy. assignee. Combination of hypoxiainducible factor-1 inhibitors and toll-like receptor-3 agonists for treating solid tumors patent WO2011128436A1. 2011.
27. Gordon LI, Evens A, Pestano L, et al., inventors; Northwestern University, USA; Oncothyreon Inc. assignee. PX-478 compositions and methods for treating lymphoma patent WO2011057220A2. 2011.
28. Peterson S, Pestano L, Fowler K, et al., inventors; Oncothyreon Inc., USA. assignee. Compounds and methods useful for treatment of diseases mediated by HIF-1 patent WO2012058325A1. 2012.
29. Lee K, Lee JH, Boovanahalli SK, et al. (Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors. J Med Chem. 2007;50(7):1675-1684.
30. Lee K, Kang JE, Park SK, et al. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol. 2010;80(7):982-989.
31. Lee K, Ban HS, Naik R, et al. Identification of malate dehydrogenase 2 as a target protein of the HIF-1 inhibitor LW6 using chemical probes. Angew Chem Int Ed Engl. 2013;52(39):10286-10289.
32. Kim BS, Lee K, Jung HJ, et al. HIF-1alpha suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1. Biochem Biophys Res Commun. 2015;458(1):14-20.
33. Won M-S, Kim H-M, Lee K, et al., inventors; Korea Research Institute of Bioscience and Biotechnology, S. Korea; Dongguk University Industry-Academic Cooperation Foundation. assignee. Preparation of aryloxyphenoxyacetyl-based compound as hypoxia inducible factor-1 inhibitor for treatment of cancers, diabetic retinopathy and arthritis patent WO2012053768A2. 2012.
34. Won MS, Lee K, Kim BK, et al., inventors; Korea Research Institute of Bioscience and Biotechnology, S. Korea; Dongguk University Industry-Academic Cooperation Foundation. assignee. preparation of disubstituted adamantyl derivatives as HIF-1 inhibitors for suppressing cancer metastasis patent WO2014084494A1. 2014.
35. Lee G, Won MS, Kim HM, et al., inventors; Ildong Pharmaceutical Co., Ltd., S. Korea. assignee. HIF-1 α inhibiting compound for angiogenesis-related disease treatment patent KR2015064857A. 2015.
36. Yin S, Kaluz S, Devi NS, et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF- 1alpha interaction with cofactors p300/CBP. Clin Cancer Res. 2012;18 (24):6623-6633.
37. Wang W, Ao L, Rayburn ER, et al. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One. 2012;7(9):e44883.
38. Van Meir E, Wang B, inventors; Emory University, USA; Georgia State University Research Foundation. assignee. Preparation of pyranopyridine derivatives for use as HIF inhibitors patent WO2011133659A2. 2011.
39. Seo YG, Jang DJ, Ahn HC, et al., inventors; SNU R&DB Foundation, S. Korea. assignee. Preparation of deguelin derivatives as HIF-1 inhibitors patent KR2012079274A. 2012.
40. Chen G, Lu X, Yang J, et al., inventors; Shenyang Pharmaceutical University, Peop. Rep. China. assignee. 2,2-dimethyl benzopyran compounds, the preparation and application patent CN102532082A. 2012.
41. Wang L, Chen G, Lu X, et al. Novel chalcone derivatives as hypoxiainducible factor (HIF)-1 inhibitor: Synthesis, anti-invasive and antiangiogenic properties. Eur J Med Chem. 2015;89:88-97.
42. Kwon HJ, Han GH, Jung HJ, et al., inventors; Industry-Academic Cooperation Foundation, Yonsei University, S. Korea. assignee. Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis patent WO2012124858A1. 2012.
43. Jung HJ, Kim KH, Kim ND, et al. Identification of a novel small molecule targeting UQCRB of mitochondrial complex III and its anti-angiogenic activity. Bioorg Med Chem Lett. 2011;21(3):1052-1056.
44. Jung HJ, Cho M, Kim Y, et al. Development of a novel class of mitochondrial ubiquinol-cytochrome c reductase binding protein (UQCRB) modulators as promising antiangiogenic leads. J Med Chem. 2014;57(19):7990-7998.
45. Janssen B, Thomson D, Muelbaier M, et al., inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Preparation of bicyclic 2,3-dihydrobenzazine compounds as inhibitors of HIF-mediated transcription and signaling under hypoxic conditions and as cell proliferation and cell division inhibitors patent WO2012130306A1. 2012.
46. Alonso J, Encinas Lopez A, Muelbaier M, et al., inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Preparation of 2,3-dihydrobenzoxazine and 2,3-dihydrobenzothiazine derivatives as HIF inhibitors useful in treatment and prevention of cancer and inflammatory diseases patent WO2011057892A1. 2011.
47. Alonso J, Lopez A, Muelbaier M, et al., inventors; European Molecular Biology Laboratory, Germany; Elara Pharmaceuticals GmbH. assignee. Preparation of toluidinylbenzenesulfonamide derivatives for use as HIF-mediated transcription inhibitors patent WO2010075869A1. 2010.
48. McLaughlin F, Lewis J, inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Compositions comprising docetaxel and a phenylsulfonamide derivative for treatment and prevention of cancer patent WO2012130314A1. 2012.
49. Toner AP, McLaughlin F, Giles FJ, et al. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance. Br J Cancer. 2013;109(8):2131-2141.
50. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002;62(15):4316-4324.
51. Chau NM, Rogers P, Aherne W, et al. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor- 1 alpha induction in response to hypoxic stress and growth factors. Cancer Res. 2005;65(11):4918-4928.
52. Baker LC, Boult JK, Walker-Samuel S, et al. The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function. Br J Cancer. 2012;106 (10):1638-1647.
53. Brown JM, Ahn GO, Kioi M, inventors; Leland Stanford Junior University, USA. assignee. Inhibition of post-radiation tumor growth by inhibiting vasculogenesis by targeting matrix metalloproteinases and bone marrow-derived cells patent US20140086901A1. 2014.
54. Liang BC, Thornton AF Jr., Sandler HM, et al. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg. 1991;75(4):559-563.
55. Moeller BJ, Cao Y, Li CY, et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429-441.
56. Muelbaier M, Alonso J, Thomson D, et al., inventors; Elara Pharmaceuticals GmbH, Germany. assignee. Preparfation of diazepanyl and piperazinyl imidazo[1,2-a]pyridine compounds as inhibitors HIF-mediated transcription and signaling under hypoxic conditions patent WO2012130322A1. 2012.
57. Jimenez Barbero J, Lopez Rodriguez ML, Alonso Hernandez D, et al., inventors; Italfarmaco, S.A., Spain. assignee. Preparation of aryl carbamates as inhibitors of fibroblast growth factor patent ES2385160A1. 2012.
58. Marin-Ramos NI, Alonso D, Ortega-Gutierrez S, et al. New inhibitors of angiogenesis with antitumor activity in vivo. J Med Chem. 2015;58 (9):3757-3766.
59. Kim S-W, Kim JH, Kim S-N, et al., inventors; Oscotec Inc., S. Korea. assignee. α-Aryl-β-methoxyacrylate derivative as HIF inhibitor and method for the preparation thereof patent WO2011132967A2. 2011.
60. Ito D, Nagao S, Yamane Y, et al., inventors; Eisai R & D Management Co., Ltd., Japan. assignee. Preparation of benzanilide derivatives for use as anticancer agents patent JP2011195484A. 2011.
61. Yasuda Y, Arakawa T, Nawata Y, et al. Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors. Bioorg Med Chem. 2015;23(8):1776-1787.
62. Crews CM, Buckley D, Ciulli A, et al., inventors; Yale University, USA; GlaxoSmithKline Intellectual Property Development Limited; Cambridge Enterprise Limited University of Cambridge. assignee. Preparation of hydroxyproline analogs as inhibitors of the VCB E3 ubiquitin ligase for treating especially anemia and ischemia patent WO2013106646A2. 2013.
63. Buckley DL, Van Molle I, Gareiss PC, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction. J Am Chem Soc. 2012;134(10):4465-4468.
64. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3(4):363-375.
65. LaVallee TM, Zhan XH, Herbstritt CJ, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002;62(13):3691-3697.
66. Moser C, Lang SA, Mori A, et al. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer. 2008;8:206.
67. LaVallee TM, Burke PA, Swartz GM, et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD- 1198. Mol Cancer Ther. 2008;7(6):1472-1482.
68. Miyamoto T, inventor; Keio University, Japan. assignee. Osteoporosis therapeutic agent, and therapeutic agent screening method patent WO2014104406A1. 2014.
69. Bai L-P, Parhira S, Zhu G-Y, et al., inventors; Macau University of Science and Technology, Macau. assignee. Preparation of 2′-epiuscharin from the Latex of Calotropis gigantea with HIF-1 Inhibitory Activity patent AU2014100813A4. 2014.
70. Chao WR, Amin K, Shi Y, et al. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis. 2011;14(1):1-16.
71. Zhou W, Sambucetti L, inventors; SRI International, USA. assignee. Synergistic anti-cancer activity of SR16388 with anti-mitotic drugs patent WO2013071214A1. 2013.
72. Chao W-R, Collins N, Sambucetti L, et al., inventors; SRI International, USA. assignee. Compositions and method for the treatment of multiple myeloma comprising (E)-3-hydroxy-21-[2′-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene patent US20110257143A1. 2011.
73. Arora PS, Lao BB, Henchey LK, et al., inventors; University of Southern California, USA; New York University. assignee. Inhibiting interaction between HIF-1α and p300/CBP with hydrogen bond surrogate-based helices using peptidomimetics patent US20150065436A1. 2015.
74. Arora PS, Olenyuk B, Bullock B, et al., inventors; New York University, USA; University of Southern California. assignee. Preparation of nonpeptidic α-helix mimetic oligooxopiperazines and their use for controlling hypoxia-inducible gene expression patent WO2013123511A1. 2013.
75. Lao BB, Grishagin I, Mesallati H, et al. In vivo modulation of hypoxiainducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A. 2014;111(21):7531-7536.
76. Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994;91 (18):8324-8328.
77. Grenert JP, Sullivan WP, Fadden P, et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem. 1997;272(38):23843-23850.
78. Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995;36(4):305-315.
79. Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem. 1995;38(19):3806-3812.
80. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino- 17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42(4):273-279.
81. Kaur G, Belotti D, Burger AM, et al. Antiangiogenic properties of 17- (dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res. 2004;10(14):4813-4821.
82. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002;62 (9):2478-2482.
83. Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002;277(33):29936-29944.
84. Liu YV, Baek JH, Zhang H, et al. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell. 2007;25(2):207-217.
85. Cheeseman MT, Brown SDM, inventors; Medical Research Council, UK. assignee. Compounds targeting the VEGF and/or HIF pathway such as sorafenib or vatalanib for use in the treatment of otitis media patent WO2011117568A1. 2011.
86. Davidson J, Hyde ML, Alberti PW. Epidemiologic patterns in childhood hearing loss: a review. Int J Pediatr Otorhinolaryngol. 1989;17 (3):239-266.
87. Kubba H, Pearson JP, Birchall JP. The aetiology of otitis media with effusion: a review. Clin Otolaryngol Allied Sci. 2000;25(3):181-194.
88. Cheeseman MT, Tyrer HE, Williams D, et al. HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants. PLoS Genet. 2011;7(10):e1002336.
89. Huang Q, Zhang Z, Zheng Y, et al. Hypoxia-inducible factor and vascular endothelial growth factor pathway for the study of hypoxia in a new model of otitis media with effusion. Audiol Neurootol. 2012;17(6):349-356.
90. Hardisty-Hughes RE, Tateossian H, Morse SA, et al. A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse. Hum Mol Genet. 2006;15(22):3273-3279.
91. Parkinson N, Hardisty-Hughes RE, Tateossian H, et al. Mutation at the Evi1 locus in Junbo mice causes susceptibility to otitis media. PLoS Genet. 2006;2(10):e149.
92. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005;65(19):9047-9055.
93. Gradishar WJ, Vogelzang NJ, Kilton LJ, et al. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. Invest New Drugs. 1995;13(2):171-174.
94. Chang AY, Kim K, Boucher H, et al. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998;82 (2):292-300.
95. Wadler S, Tenteromano L, Cazenave L, et al. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol. 1994;34(3):266-269.
96. Foster BJ, Clagett-Carr K, Shoemaker DD, et al. Echinomycin: the first bifunctional intercalating agent in clinical trials. Invest New Drugs. 1985;3(4):403-410.
97. Liu Y, Wang Y, Liu Y, et al., inventors; Oncoimmune Inc., USA; Sunvita Therapeutics, Llc. assignee. Uses of hypoxia-inducible factor inhibitors for treating hematol. cancer patent WO2011068563A1. 2011.
98. Wang Y, Liu Y, Malek SN, et al. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8 (4):399-411.
99. Rao KV, Alvarez FM. Manassantins A/B and saucerneol: novel biologically active lignoids from Saururus cernuus. Tetrahedron Lett. 1983;24(45):4947-4950.
100. Hodges TW, Hossain CF, Kim YP, et al. Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-Odemethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. J Nat Prod. 2004;67(5):767-771.
101. Hossain CF, Kim YP, Baerson SR, et al. Saururus cernuus lignans-potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem Biophys Res Commun. 2005;333(3):1026-1033.
102. Hwang BY, Lee JH, Nam JB, et al. Lignans from Saururus chinensis inhibiting the transcription factor NF-kappaB. Phytochemistry. 2003;64(3):765-771.
103. Kim JY, Kang JS, Kim HM, et al. Inhibition of phenotypic and functional maturation of dendritic cells by manassantin a. J Pharmacol Sci. 2009;109(4):583-592.
104. Kim SJ, Lu Y, Kwon O, et al. Manassantin A isolated from Saururus chinensis inhibits 5-lipoxygenase-dependent leukotriene C4 generation by blocking mitogen-activated protein kinase activation in mast cells. Biol Pharm Bull. 2011;34(11):1769-1772.
105. Kasper AC, Moon EJ, Hu X, et al. Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations. Bioorg Med Chem Lett. 2009;19(14):3783-3786.
106. Xie P, Chen X, Jiao X, et al., inventors; Institute of Mataria Medica, Chinese Academy of Medical Sciences, Peop. Rep. China. assignee. Saucernetin structurally simplified substances as HIF-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer patent WO2012163264A1. 2012.
107. Lang L, Liu X, Li Y, et al. A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth. PLoS One. 2014;9(6): e99584.
108. Akinboye ES, Bakare O. Biological activities of emetine. Open Nat Prod J. 2011;4:8-15.
109. Zhou YD, Kim YP, Mohammed KA, et al. Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells. J Nat Prod. 2005;68(6):947-950.
110. Ashcroft M, Jones K, inventors; UCL Business PLC, UK. assignee. Antitumor HIF inhibitors patent WO2015079213A1. 2015.
111. Zhang D, Chen X, Wang C, et al., inventors; Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China. assignee. A Triptolidenol derivative and application as antitumor agents patent CN104513290A. 2015.
112. Kwon HJ, Lee BR, inventors; Office of Research Affairs/UIF, Yonsei University, S. Korea. assignee. Matairesinol derivatives for inhibiting angiogenesis patent KR2013104769A. 2013.
113. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B. 2015;5(5):378-389.
114. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004;6(1):33-43.
115. Shin DH, Chun YS, Lee DS, et al. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008;111(6):3131-3136.
116. Li SH, Shin DH, Chun YS, et al. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF- 1{alpha}. Mol Cancer Ther. 2008;7(12):3729-3738.
117. Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci. 2012;37(9):364-372.
118. Zhao J, Du F, Shen G, et al. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis. 2015;6:e1600.
119. Dixon DD, Grina J, Josey JA, et al., inventors; Peloton Therapeutics, Inc., USA. assignee. Preparation of aryl ethers as HIF- 2α inhibitors and use in treating cancer patent WO2015035223A1. 2015.
120. Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG- 4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665-1673.
121. Yang L, Xu Y, Li W, et al. Diacylglycerol kinase (DGK) inhibitor II (R59949) could suppress retinal neovascularization and protect retinal astrocytes in an oxygen-induced retinopathy model. J Mol Neurosci. 2015;56(1):78-88.
122. Temes E, Martin-Puig S, Acosta-Iborra B, et al. Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J Biol Chem. 2005;280(25):24238-24244.
123. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134(5):703-707.
124. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664-3671.
125. Li B, Qiu B, Lee DS, et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 2014;513(7517):251-255.